Telmisartan
Is It Right for You?
A complete guide to Telmisartan — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Telmisartan?
Telmisartan is an angiotensin II receptor blocker (ARB), a class of medication used primarily to treat high blood pressure (hypertension) and to protect the kidneys in patients with type 2 diabetes. It is available as oral tablets in doses of 20 mg, 40 mg, and 80 mg, taken once daily.
ARBs like telmisartan are among the most commonly prescribed antihypertensive medications worldwide and are a cornerstone of modern blood pressure management. They are particularly favoured in patients who experience a persistent dry cough with ACE inhibitors (an alternative but related drug class), as ARBs produce the same blood pressure-lowering benefits through a slightly different mechanism without causing this side effect.
Telmisartan has a distinctive pharmacological advantage: it has the longest half-life of all ARBs (approximately 24 hours), allowing it to provide consistent, sustained blood pressure control across the full 24-hour dosing interval, including the critical early-morning hours — the period when blood pressure typically surges and when cardiovascular events such as heart attacks and strokes are most frequent.
In addition to hypertension, telmisartan is licensed for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease or with type 2 diabetes with end-organ damage, where it reduces the risk of heart attack, stroke, and cardiovascular death.
Telmisartan is a prescription-only medication in the UK. A clinician must assess your blood pressure, kidney function, electrolytes, and medical history before prescribing.
What Conditions Is Telmisartan Used For?
Telmisartan is indicated for:
primary indication; telmisartan effectively lowers blood pressure in patients with mild, moderate, or severe hypertension as monotherapy or in combination with other antihypertensives.
in patients aged 55 years or older with a high risk of cardiovascular events due to established coronary artery disease, stroke, peripheral arterial disease, or type 2 diabetes with target organ damage, telmisartan reduces the risk of myocardial infarction, stroke, and cardiovascular death.
ARBs are recommended for patients with type 2 diabetes and proteinuria or microalbuminuria, where they slow the progression of kidney disease independently of their blood pressure-lowering effect.
Telmisartan effectively controls blood pressure but does not cure hypertension. Most patients require lifelong treatment, and lifestyle modifications remain essential alongside medication.
How Does Telmisartan Work?
Telmisartan works by selectively blocking the angiotensin II type 1 (AT1) receptor — the primary receptor through which angiotensin II exerts its cardiovascular and renal effects.
Angiotensin II is a powerful vasoconstrictor produced by the renin-angiotensin-aldosterone system (RAAS) — a hormonal cascade that plays a central role in regulating blood pressure, fluid balance, and electrolyte homeostasis. Angiotensin II raises blood pressure by:
- Causing direct vasoconstriction (narrowing) of blood vessels
- Stimulating the adrenal glands to release aldosterone, which promotes sodium and water retention by the kidneys (increasing blood volume)
- Stimulating the release of antidiuretic hormone (ADH), further promoting water retention
By blocking the AT1 receptor, telmisartan prevents all of these blood pressure-raising effects, resulting in vasodilation, reduced blood volume, and a lowering of systemic vascular resistance and blood pressure.
Unlike ACE inhibitors, telmisartan does not prevent the breakdown of bradykinin — the mechanism responsible for the dry cough and angioedema associated with ACE inhibitors. This makes ARBs better tolerated in patients sensitive to these effects.
Telmisartan also has partial agonist activity at the PPAR-gamma receptor, a nuclear receptor involved in insulin sensitivity and lipid metabolism. This may contribute to additional metabolic benefits, including modest improvements in insulin resistance and lipid profiles, though the clinical significance of this effect in everyday practice remains an area of ongoing research.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take telmisartan once daily at the same time each day, with or without food. Consistency in timing supports stable blood pressure control across the 24-hour period.
Do not take potassium supplements, potassium-containing salt substitutes, or potassium-sparing diuretics without clinician guidance — ARBs raise serum potassium, and additional potassium can cause hyperkalaemia with serious cardiac consequences.
Monitor your blood pressure at home where possible — this helps assess treatment response and guides dose adjustments at your next clinical review.
Do not stop telmisartan suddenly without speaking to your clinician. Abrupt cessation can cause a rapid rebound in blood pressure.
Stay well hydrated — dehydration (from heat, illness, or excessive exercise) can cause blood pressure to drop excessively, leading to dizziness and a risk of falls or acute kidney injury.
Side Effects of Telmisartan
Telmisartan is generally well tolerated, with a lower side effect burden than ACE inhibitors.
- Dizziness or light-headedness
- Headache
- Fatigue
- Nasopharyngitis
- Back pain
- Hyperkalaemia — muscle weakness, palpitations; risk increased in renal impairment.
Telmisartan can affect renal function and potassium levels. Regular monitoring is essential, especially in patients with diabetes or chronic kidney disease.
Drug Interactions
Telmisartan may interact with other RAAS agents, NSAIDs, and potassium-sparing diuretics. Always inform your clinician about all medications you are taking.
Dual or triple RAAS blockade significantly increases risk of hypotension, hyperkalaemia, and acute renal failure. Avoid combination, particularly in diabetic patients (contraindicated by guideline).
Contraindicated in the second and third trimesters. Causes foetal renal dysgenesis, oligohydramnios, limb contractures, and death.
Reduce the antihypertensive effect of telmisartan and significantly increase risk of acute kidney injury, particularly in elderly, dehydrated, or renally impaired patients. Avoid regular concurrent use.
Additive hyperkalaemia risk. Avoid unless closely monitored.
Important Warnings
Telmisartan must not be used during the second or third trimester of pregnancy, and should be avoided if possible in the first trimester. ARBs cause severe foetal abnormalities including renal failure, limb deformities, and death. Women of childbearing age must use effective contraception and discontinue telmisartan immediately if pregnancy is suspected or confirmed.
Though less common than with ACE inhibitors, angioedema has been reported with ARBs. Swelling of the face, lips, tongue, or throat requires immediate discontinuation and emergency medical care.
Telmisartan must be used with extreme caution — or avoided — in patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. RAAS blockade in this context can cause precipitous deterioration of kidney function.
Patients who are volume-depleted (from diuretics, low-salt diet, vomiting, diarrhoea, or excessive sweating) are at increased risk of symptomatic hypotension on initiation. Volume status should be corrected before starting telmisartan, or a low starting dose should be used with close monitoring.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Telmisartan FAQs
Yes. A licensed clinician can assess your blood pressure and medical history via a telehealth consultation and prescribe telmisartan if appropriate. Access to recent blood pressure readings and blood test results (particularly renal function and potassium) will help the clinician make an accurate assessment.
Both drug classes lower blood pressure through the RAAS but work at slightly different points in the pathway. ACE inhibitors cause a persistent dry cough in approximately 15–20% of patients due to bradykinin accumulation — a side effect that does not occur with ARBs. Telmisartan is commonly prescribed for patients who cannot tolerate ACE inhibitors due to cough, and may also be preferred in certain patient groups such as those with diabetes or metabolic syndrome.
Blood pressure-lowering effects begin within a few hours of the first dose, with maximum effect typically reached within 4–8 weeks of treatment. Full assessment of efficacy is usually made after 4–6 weeks.
For most patients with essential hypertension, telmisartan is a long-term or lifelong treatment. Blood pressure does not remain controlled if treatment is stopped. However, in some patients — particularly those who make significant lifestyle changes — doses may be reduced or medications adjusted over time.
In most patients, telmisartan protects the kidneys — it is specifically recommended to slow the progression of diabetic kidney disease. However, in patients with certain kidney conditions (such as renovascular disease or advanced chronic kidney disease), it can sometimes cause a fall in kidney function. This is why renal function monitoring is important, particularly on initiation.
Paracetamol is safe and is the recommended first-choice painkiller for patients on telmisartan. Regular use of NSAIDs such as ibuprofen is not recommended, as they reduce the antihypertensive effect and can cause acute kidney injury in combination with ARBs.